Pfetin as a prognostic biomarker for gastrointestinal stromal tumor: Validation study in multiple clinical facilities

Japanese Journal of Clinical Oncology

Volumn 41, Issue 10, 2011, Pages 1194-1202

  Kubota, Daisuke ^a,b   Orita, Hajime ^c   Yoshida, Akihiko ^d,e   Gotoh, Masahiro ^a   Kanda, Tatsuo ^f   Tsuda, Hitoshi ^d   Hasegawa, Tadashi ^g   Katai, Hitoshi ^d   Shimada, Yasuhiro ^d   Kaneko, Kazuo ^b   Kawai, Akira ^d   Kondo, Tadashi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^g SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PFETIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTICENTER STUDY; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PIPERAZINES; PROTEINS; PYRIMIDINES; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80053502871     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr121     Document Type: Article

References (19)

1. Joensuu H, Kindblom LG. Gastrointestinal stromal tumors-a review. Acta Orthop Scand Suppl 2004;75:62-71.
2. Miettinen M, El-Rifai W, Sobin LH, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002;33:478-83.
3. Rumessen JJ, Peters S, Thuneberg L. Light- and electron microscopical studies of interstitial cells of Cajal and muscle cells at the submucosal border of human colon. Lab Invest 1993;68:481-95.
4. Zhong JH, Ma L, Li LQ, Ru HM, Zhao YN. Adjuvant imatinib for gastrointestinal stromal tumors: the current situation and problems. Scand J Gastroenterol 2011;46:645-51.
5. Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:1097-104.
6. Blay JY, von Mehren M, Blackstein ME. Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors. Cancer 2010;116:5126-37.
7. Le Cesne A, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol 2010;11:942-9.
8. Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004;40:689-95.
9. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42:1093-103.
10. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006;24:4764-74.
11. Schneider-Stock R, Boltze C, Lasota J, Miettinen M, Peters B, Pross M, et al. High prognostic value of p16INK4 alterations in gastrointestinal stromal tumors. J Clin Oncol 2003;21:1688-97.
12. Schneider-Stock R, Boltze C, Lasota J, Peters B, Corless CL, Ruemmele P, et al. Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. Clin Cancer Res 2005;11:638-45.
13. Suehara Y, Kondo T, Seki K, Shibata T, Fujii K, Gotoh M, et al. Pfetin as a prognostic biomarker of gastrointestinal stromal tumors revealed by proteomics. Clin Cancer Res 2008;14:1707-17.
14. Resendes BL, Kuo SF, Robertson NG, Giersch AB, Honrubia D, Ohara O, et al. Isolation from cochlea of a novel human intronless gene with predominant fetal expression. J Assoc Res Otolaryngol 2004;5:185-202.
15. Kikuta K, Gotoh M, Kanda T, Tochigi N, Shimoda T, Hasegawa T, et al. Pfetin as a prognostic biomarker in gastrointestinal stromal tumor: novel monoclonal antibody and external validation study in multiple clinical facilities. Jpn J Clin Oncol 2010;40:60-72.
16. Hamilton SR, Aaltonen LA, International Agency for Research on Cancer, World Health Organization. Pathology and Genetics of Tumours of the Digestive System. Lyon: IARC Press 2000.
17. Hasegawa T, Matsuno Y, Shimoda T, Hirohashi S. Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol 2002;33:669-76.
18. Kaplan EL, Paul M. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
19. Cox D. Regression models and life tables. J R Stat Soc 1972;34:187-220.